StemRIM Inc
TSE:4599
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
StemRIM Inc
Operating Expenses
StemRIM Inc
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
StemRIM Inc
TSE:4599
|
Operating Expenses
-¥1.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
SanBio Co Ltd
TSE:4592
|
Operating Expenses
-¥3.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-7%
|
|
|
GNI Group Ltd
TSE:2160
|
Operating Expenses
-¥22.5B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-32%
|
|
|
PeptiDream Inc
TSE:4587
|
Operating Expenses
-¥12.5B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-39%
|
|
|
Takara Bio Inc
TSE:4974
|
Operating Expenses
-¥25B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-6%
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Operating Expenses
-¥2.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-7%
|
|
StemRIM Inc
Glance View
StemRIM, Inc. engages in the research and development of regeneration inducing medicine. The company is headquartered in Ibaraki-Shi, Osaka-Fu and currently employs 46 full-time employees. The company went IPO on 2019-08-09. The firm is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
See Also
What is StemRIM Inc's Operating Expenses?
Operating Expenses
-1.9B
JPY
Based on the financial report for Jan 31, 2026, StemRIM Inc's Operating Expenses amounts to -1.9B JPY.
What is StemRIM Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
3%
Over the last year, the Operating Expenses growth was 10%. The average annual Operating Expenses growth rates for StemRIM Inc have been 2% over the past three years , 3% over the past five years .
